SK-NEP-1 Cells

SK-NEP-1 is a human cell line originally derived from a nephroblastoma, also known as Wilms' tumor, a common pediatric renal malignancy. This cell line has been used extensively in preclinical research to study nephroblastoma biology and to evaluate novel therapeutic approaches for treating Wilms' tumor. However, later molecular characterizations revealed that SK-NEP-1 expresses the EWS-FLI1 fusion gene, which is characteristic of Ewing sarcoma, indicating that this cell line is more representative of the Ewing family of tumors rather than Wilms' tumor. This discovery has important implications for interpreting past research that utilized SK-NEP-1, as its biological characteristics align more closely with Ewing sarcoma rather than anaplastic Wilms' tumor. Research involving SK-NEP-1 has shown that it is responsive to chemotherapy agents such as vincristine, which inhibits microtubule polymerization, leading to G2/M phase arrest and apoptosis. Additionally, combination therapies using natural compounds like andrographolide have demonstrated synergistic effects in increasing the cytotoxicity of vincristine on SK-NEP-1 cells, primarily through the PI3K-AKT-p53 signaling pathway. This combination was shown to induce apoptosis in SK-NEP-1 cells, both in vitro and in vivo, making it a promising approach for treating tumors that share the molecular characteristics of SK-NEP-1. SK-NEP-1 is thus a critical model for studying the molecular underpinnings of pediatric renal and Ewing sarcoma tumors and for evaluating the effectiveness of drug combinations aimed at improving therapeutic outcomes in these cancer types. Its use in research has contributed to understanding drug-induced apoptosis and the potential of targeting specific signaling pathways like PI3K-AKT-p53 in cancer therapy.